is also available on the CPSC Web site at *http://www.cpsc.gov.*

Dated: July 6, 2010.

Todd A. Stevenson,

Secretary, Consumer Product Safety Commission. [FR Doc. 2010–16918 Filed 7–9–10; 8:45 am] BILLING CODE 6355–01–P

DEPARTMENT OF DEFENSE

Department of the Army

Availability for Non-Exclusive or Partially Exclusive Licensing of a U.S. Patent Application

AGENCY: Department of the Army, DoD. **ACTION:** Notice.

SUMMARY: Announcement is made of the availability for licensing of the invention set forth in U.S. Patent 7,632,659, which issued on December 15, 2009, entitled "Use of Shigella Invaplex to Transport Functional Proteins and Transcriptionally Active Nucleic Acids Across Mammalian Cell Membranes In Vitro and In Vivo," and U.S. Patent Application Serial No. 12/ 563,794, entitled "Use of Shigella Invaplex to Transport Functional Proteins and Transcriptionally Active Nucleic Acids Across Mammalian Cell Membranes In Vitro and In Vivo," filed September 21, 2009. U.S. Patent Application Serial No. 12/563,794 is a continuation application of U.S. Patent 7,632,659. Foreign rights are also available for licensing (PCT/US2004/ 039100). The United States Government, as represented by the Secretary of the Army, has rights to this invention. ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street,

Fort Detrick, Frederick, MD 21702– 5012. FOR FURTHER INFORMATION CONTACT: For

patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619–7808. For licensing issues, Dr. Paul Mele, Office of Research and Technology Applications (ORTA), (301) 619–6664, both at telefax (301) 619–5034.

SUPPLEMENTARY INFORMATION: The inventions relate to the use of Invaplex to transport materials, including functional proteins and biologically active nucleic acids, across eukaryotic cell membranes.

Brenda S. Bowen,

Army Federal Register Liaison Officer. [FR Doc. 2010–16889 Filed 7–9–10; 8:45 am] BILLING CODE 3710–08–P

DEPARTMENT OF DEFENSE

Department of the Army

Availability for Non-Exclusive or Partially Exclusive Licensing of a U.S. Patent Application

AGENCY: Department of the Army, DoD. **ACTION:** Notice.

SUMMARY: Announcement is made of the availability for licensing of the invention set forth in U.S. Patent Application Serial No. 11/727,486, entitled "Artificial Invaplex," filed March 27, 2007. Foreign rights are also available for licensing (PCT/US2007/007482). The United States Government, as represented by the Secretary of the Army, has rights to this invention.

ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR–JA, 504 Scott Street, Fort Detrick, Frederick, MD 21702– 5012.

FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619–7808. For licensing issues, Dr. Paul Mele, Office of Research and Technology Applications (ORTA), (301) 619–6664, both at telefax (301) 619–5034.

SUPPLEMENTARY INFORMATION: The invention relates to an artificial invasin complex hat can facilitate the transport of biomolecules, therapeutics and antibiotics across cell membranes in a manner similar to native *Shigella* Invaplex.

Brenda S. Bowen,

Army Federal Register Liaison Officer. [FR Doc. 2010–16897 Filed 7–9–10; 8:45 am] BILLING CODE 3710–08–P

DEPARTMENT OF DEFENSE

Department of the Army

Availability for Non-Exclusive or Partially Exclusive Licensing of a U.S. Patent Application

AGENCY: Department of the Army, DoD. **ACTION:** Notice.

SUMMARY: Announcement is made of the availability for licensing of the invention set forth in U.S. Patent Application Serial No. 12/149,076, entitled "Combinations of Gene Deletions for Live Attenuated *Shigella* Vaccine Strains," filed April 25, 2008. Foreign rights are also available for licensing (PCT/US2008/005342). The United States Government, as

represented by the Secretary of the Army, has rights to this invention. **ADDRESSES:** Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR–JA, 504 Scott Street, Fort Detrick, Frederick, MD 21702– 5012.

FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619–7808. For licensing issues, Dr. Paul Mele, Office of Research and Technology Applications (ORTA), (301) 619–6664, both at telefax (301) 619–5034.

SUPPLEMENTARY INFORMATION: The invention relates generally to *Shigella* vaccine, strains, their use in vaccines, and the methods for treatment of dysentery.

Brenda S. Bowen,

Army Federal Register Liaison Officer. [FR Doc. 2010–16894 Filed 7–9–10; 8:45 am] BILLING CODE 3710–08–P

DEPARTMENT OF DEFENSE

Department of the Army

Availability for Non-Exclusive or Partially Exclusive Licensing of a U.S. Patent Application

AGENCY: Department of the Army, DoD. **ACTION:** Notice.

SUMMARY: Announcement is made of the availability for licensing of the invention set forth in U.S. Patent Application Serial No. 11/132,199, entitled "Construction of Live Attenuated *Shigella* Vaccine Strains that Express CFA/I Antigens (CFAB and CFAE) and the B Subunit of Heat-Labile Enterotoxin (LTB) From Enterotoxigenic *E. Coli,*" filed May 19, 2005. The United States Government, as represented by the Secretary of the Army, has rights to this invention.

ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR–JA, 504 Scott Street, Fort Detrick, Frederick, MD 21702– 5012.

FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619–7808. For licensing issues, Dr. Paul Mele, Office of Research and Technology Applications (ORTA), (301) 619–6664, both at telefax (301) 619–5034.

SUPPLEMENTARY INFORMATION: The invention relates to materials and methodologies for preparing multivalent vaccines, recombinant DNA expression